← Back

Wire · opportunities

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fda.gov →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The FDA approved Infilbray (venglustat), the first drug to treat neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients, which can cross the blood-brain barrier to reduce harmful substance accumulation in the brain and body.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You just gained access to a rare neurological treatment market with FDA backing for Type 3 Gaucher disease. Start exploring patient groups and specialists focused on rare genetic disorders to pitch your solutions now.

◆ Coverage

2 sources · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseaseneurological-treatmentdrug-innovationclinical-trial